---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-22-000012"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:49:42.054814+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amneal reports Q1 2022 net revenue $498M (+1% YoY), GAAP net loss $2M, adj. EPS $0.12

## Summary
- Net revenue $498M vs $493M in Q1 2021; driven by generics and AvKARE distribution, partially offset by Zomig loss of exclusivity.
- GAAP net loss $2M ($0.01 diluted loss per share) vs net income $7M in Q1 2021.
- Adjusted EBITDA $100M including $5M R&D milestone expense; adjusted diluted EPS $0.12.
- Company maintains 2022 full-year outlook; highlights FDA approvals for two biosimilars and Saol Baclofen acquisition.
- Growth strategy focused on biosimilars, injectables, and advancing R&D pipeline.

## SEC filing metadata
- accession: 0001723128-22-000012
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312822000012/0001723128-22-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312822000012/amrx-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-22-000012
- JSON: https://secwatch.observer/filing/0001723128-22-000012.json
- Plain text: https://secwatch.observer/filing/0001723128-22-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.